Protagonist Therapeutics, Inc. (PTGX)
134.58
+5.83
(+4.53%)
USD |
NASDAQ |
Oct 19, 16:00
134.58
0.00 (0.00%)
After-Hours: 20:00
Protagonist Therapeutics Price to Book Value : 10.34 for Oct. 19, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 9.894 |
| October 15, 2026 | 10.49 |
| October 14, 2026 | 10.47 |
| October 13, 2026 | 10.64 |
| October 12, 2026 | 11.13 |
| October 09, 2026 | 11.05 |
| October 08, 2026 | 10.75 |
| October 07, 2026 | 10.83 |
| October 06, 2026 | 10.66 |
| October 05, 2026 | 10.81 |
| October 02, 2026 | 10.76 |
| October 01, 2026 | 10.70 |
| September 30, 2026 | 10.83 |
| September 29, 2026 | 10.83 |
| September 28, 2026 | 10.95 |
| September 25, 2026 | 10.90 |
| September 24, 2026 | 10.55 |
| September 23, 2026 | 10.66 |
| September 22, 2026 | 11.15 |
| September 21, 2026 | 11.14 |
| September 18, 2026 | 10.99 |
| September 17, 2026 | 11.04 |
| September 16, 2026 | 10.98 |
| September 15, 2026 | 11.02 |
| September 14, 2026 | 11.36 |
| Date | Value |
|---|---|
| September 11, 2026 | 11.39 |
| September 10, 2026 | 11.16 |
| September 09, 2026 | 11.15 |
| September 08, 2026 | 11.22 |
| September 04, 2026 | 11.20 |
| September 03, 2026 | 11.44 |
| September 02, 2026 | 11.23 |
| September 01, 2026 | 11.26 |
| August 31, 2026 | 11.35 |
| August 28, 2026 | 11.09 |
| August 27, 2026 | 11.49 |
| August 26, 2026 | 11.64 |
| August 25, 2026 | 11.57 |
| August 24, 2026 | 11.89 |
| August 21, 2026 | 11.86 |
| August 20, 2026 | 11.58 |
| August 19, 2026 | 11.91 |
| August 18, 2026 | 12.09 |
| August 17, 2026 | 12.19 |
| August 14, 2026 | 11.92 |
| August 13, 2026 | 11.64 |
| August 12, 2026 | 11.68 |
| August 11, 2026 | 11.40 |
| August 10, 2026 | 11.53 |
| August 07, 2026 | 11.21 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Johnson & Johnson | 7.200 |
| AbbVie, Inc. | -- |
| Gilead Sciences, Inc. | 16.06 |
| Alnylam Pharmaceuticals, Inc. | 23.05 |
| BioMarin Pharmaceutical, Inc. | 1.673 |
Price to Book Value Related Metrics
| PE Ratio | 129.78 |
| PS Ratio | 32.13 |
| PEG Ratio | 2.850 |
| Price to Free Cash Flow | 69.39 |
| Price | 134.58 |
| Earnings Yield | 0.77% |
| Market Cap | 8.704B |
| PEGY Ratio | 2.850 |
| Operating PE Ratio | 155.30 |
| Normalized PE Ratio | 129.77 |